Expression of programmed cell death-1 (PD-1) and its ligand PD-L1 and PD-L2 as well as the enzyme indolamin 2,3-dioxygenase (IDO) in primary lymphomas of the skin

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00010675

Enrollment

Registered

2016-06-30

Start date

2016-07-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lymphoma of the skin C83

Interventions

Group 1: Immunohistochemical study of expression of PD - 1 , PD - L1 , PD - L2 and IDO in skin lymphomas

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: none

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Expression of PDL1 and PDL2 with PFS and overall survival	—

Countries

Germany

Contacts

Public ContactDagmar von Bubnoff

Universitäts-Klinik für Dermatologie undVenerologie,

dagmar.bubnoff@uniklinik-freiburg.de0761-270-67440

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026